A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 11 sites in 2 countries. Open to participants aged 42 Days to 84 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-15.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 12th largest by enrollment, is one of 3 that started in 2022, is one of 14 in phase 3, and was the 13th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States
Ages 2 mo–15 mo · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 42 Days to 84 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2022.
This study's enrollment of 541 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 668 across the 19 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 4 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 31st largest by enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2022, is one of 33 in phase 3, and was the 60th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
1 of the studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in infants and toddlers.
This study is enrolling participants who are:
Participants will receive either the study vaccine (20vPnC) or a licensed vaccine (13vPnC) as a 4-dose schedule as a shot in the muscle. Participants will receive Dose 1 on study day 1. Dose 2 will be given 28-70 days after Dose 1, and Dose 3 will be given 28-70 days after Dose 2. Dose 4 will be given at 365-455 days (approximately 12-15 months) of age.
Participation in the study will take approximately 15 months, during which participants will come to the study clinic for 6 times. The study team will ask questions about the participant's health and take some blood samples during the visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pneumococcal conjugate vaccine (20vPnC)
Biological: 20-valent pneumococcal conjugate vaccine
Pneumococcal conjugate vaccine (13vPnC)
Biological: 13-valent pneumococcal conjugate vaccine
20-valent pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccine
Percentage of participants in India and Taiwan with local reactions (redness, swelling, and pain at the injection site), separately by country
Prompted local reactions after each dose
Time frame: Day 7
Percentage of participants in India and Taiwan with systemic events (fever, decreased appetite, drowsiness/increased sleep, and irritability), separately by country
Prompted systemic reactions after each dose
Time frame: Day 7
Percentage of participants in India and Taiwan with adverse events (AEs) from Dose 1 through 1 month after Dose 3 in each group, separately by country
Adverse events occurring from Dose 1 to 1 month after Dose 3 in each group
Time frame: Dose 1 to 1 month after Dose 3
Percentage of participants from India and Taiwan with AEs from Dose 4 through 1 month after Dose 4 in each group, separately by country
Adverse events occurring from Dose 4 to 1 month after Dose 4 in each group
Time frame: Dose 4 to 1 month after Dose 4
Percentage of participants in India and Taiwan with SAEs from Dose 1 through 1 month after Dose 4 in each group, separately by country
SAEs occurring up to 1 month after Dose 4 in each group
Time frame: Dose 1 to 1 month after Dose 4
GMCs of serotype-specific IgG concentrations in Indian participants 1 month after Dose 4 in each vaccine group
IgG GMCs for the 20vPnC serotypes 1 month after Dose 4, Indian participants only
Time frame: 1 month after Dose 4
Geometric mean concentrations (GMCs) of serotype-specific IgG concentrations 1 month after Dose 3 in each vaccine group, separately by country
IgG GMCs for the 20vPnC serotypes 1 month after Dose 3
Time frame: 1 month after Dose 3
Percentages of participants in India and Taiwan with predefined serotype-specific IgG concentration for the 20vPnC serotypes at approximately 1 month after Dose 3 in each vaccine group, separately by country
IgG concentrations for 20vPnC serotypes 1 month after Dose 3
Time frame: 1 month after Dose 3
GMCs of serotype-specific IgG concentrations in Taiwanese participants 1 month after Dose 4 in each vaccine group
IgG GMCs for the 20vPnC serotypes 1 month after Dose 4, Taiwanese participants only
Time frame: 1 month after Dose 4
Percentages of participants in India and Taiwan with predefined serotype-specific IgG concentrations for the 20vPnC serotypes at approximately 1 month after Dose 4 in each vaccine group, separately by country
IgG concentrations for 20vPnC serotypes 1 month after Dose 4
Time frame: 1 month after Dose 4
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Sep 2022 to primary completion in Sep 2025, 36 months.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 36 months is above that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine